Aterovax is a biopharmaceutical company dedicated to improving diagnosis and treatment of atherosclerosis.

News

BIOMNIS Signs Collaboration with ATEROVAX

Read more

ATEROVAX Signs Distribution Agreement with SPI-BIO

Read more

Aterovax develops innovative solutions to predict , diagnose, prevent and treat cardiovascular disease through its unique understanding of atherosclerosis.

Our first product, ATEROVAX sPLA2 Activity Test, is now available for research use only. The test detects the activity of the enzyme sPLA2, which has been validated as a potent biomarker of the vulnerable or destabilised atherosclerotic plaque.

 

Next coming event : ESC 2010 Congress
European Society of Cardiology, Stockholm-Sweden, 28 Aug - 01 Sep 2010
A face to face meeting? Contact us!